Gabriel Baertschi has been announced as Grünenthal Group’s CEO. The company is an independent, family-owned pharmaceutical company operating in Aachen, Germany. The veteran has more than 20 years of international experience in the industry. Most recent, Baertschi served as President and General Manager, Japan at AstraZeneca. Under his leadership, the company ranked number six for Japan’s bestselling pharma companies.
Baertschi is taking over for Dr. Eric-Paul Pâques who served 23 years in the company.
“Grünenthal, as global leader in pain therapy, is highly committed to research and innovation. He has a track record of bringing innovative pain therapies to patients around the world. As a family-owned company, Grünenthal takes a long term view on innovation and covers the whole value chain,” says Baertschi.
Dr. Amber Salzman Appointed CEO at Adverum Biotechnologies
As Adverum Biotechnologies, Inc.’s CEO Paul B. Cleveland settles into his new position as Chairman of the company’s Board of Directors, he is passing the baton over to Amber Salzman, PhD, who is now CEO.
“I believe that the time has come for me to retire from a full-time CEO role, and I believe that with Amber as CEO, the company will flourish—and that will benefit both patients and shareholders,” says Cleveland.
Dr. Salzman joined the company in 2016 as President and CFO. She is also Co-founder and served as President and CEO of Annapurna Therapeutics. She is widely recognized for her work in the rare disease community, having lead Cardiokine Inc., prior to its acquisition by Cornerstone Therapeutics, as CEO from 2009 to 2011.
Introduces James Gorman, MD, PhD as its Vice President of Strategic Planning and Portfolio Management. He brings more than 20 years of experience in the field. He made strides in his career while working with Abbott Laboratories where he was accountable for classifying, recommending, and coordinating strategies to maximize the company’s biologic business. He also championed the acquisition of Humira, which earned him the Abbott President’s Award.
Announces the addition of Ellen J. Kullman to its Board of Directors. Specifically, she has been assigned as a member of the audit committee. Kullman most recent served as President, Chair, and CEO of E.I. du Pont de Nemours and Company from 2009 to 2015.
Diffusion Pharmaceuticals Inc.
Shares the formation of its advisory board, which includes Karen C. Johnston, MD, MSc. She is Chair of Neurology and Professor of Public Health Sciences at the University of Virginia. Her studies are based on the design and execution of middle phase and Phase III clinical trials. William R. Hiatt, MD, was also added to the advisory board. Hiatt is a Cardiovascular Research Professor at The University of Colorado School of Medicine, Division of Cardiology. He is also president of CPC Clinical Research.
Generic Pharmaceutical Association (GPhA)
Announced that Jeffrey K. Francer joins as SVP and General Counsel. Previously, he served as Associate Chief Counsel of the FDA. He will help the group address complex issues, such as drug affordability during the next presidential administration.
Kite Pharma, Inc.
Welcomes Christine Cassiano as Senior Vice President of Corporate Communications and Investor Relations, and also part of the executive committee. Cassiano is acknowledged for her innovative communication methods in corporate positioning, issues management, employee engagement, commercialization, and investor relations.
Lion Biotechnologies, Inc.
Titles Gregory T. Schiffman, MBA as Chief Financial Officer. Schiffman has 15 years experience in financial operations and strategy of publicly traded healthcare companies, which include Dendreon, Affymetrix, and Applied Biosystems.
Reveals its latest addition, George M. Garibaldi, MD as an independent non-executive director on its board. He brings 25 years of experience in global pharmaceuticals. His studies centralize in areas of neurology and psychiatry. He is a member of the American Academy of Child and Adolescent Psychiatry. Janet Vergis also joins the board as an independent non-executive director. The veteran has more than 25 years of practice in the arena with a reputation of amplifying businesses. She previously managed a $6 billion portfolio at Johnson & Johnson as President of Janssen Pharmaceutical, McNeil Pediatrics, and Ortho-McNeill Neurologics.
Myovant Sciences Ltd.
Welcomes former U.S. Secretary of Health and Human Services, Kathleen Sebelius, to its Board of Directors. She is renowned as the second female governor of Kansas, where she served from 2003 to 2009. She is presently a board member of Dermira, Inc., Humacyte, Inc., Grand Rounds, Inc., and Hampton Creek, Inc.
Noven Pharmaceuticals, Inc.
Names Ralph Lipp, PhD as Vice President and Chief Scientific Officer. He will report to CEO Jeff Mihm. His main responsibility is to lead all research and development endeavors for the company’s transdermal drug delivery program. The veteran and founder of Lipp Life Sciences LLC has 25 years experience in the industry.
OncBioMune Pharmaceuticals, Inc.
Welcomes Brian Barnett, MD to its advisory board. He is currently Senior Medical Director, Neratinib, Medical Affairs at Puma Biotechnology. Dr. Barnett has conducted a number of presentations at top oncology conferences regarding to the regulation of cancer through immune therapy.
Appoints Richard Gregory, PhD, to its Board of Directors. He is presently Chief Scientific Officer and Executive VP of Research at Immunogen. He is the author of 60 peer- reviewed publications and fellow of the American Institute for Medical and Biological Engineering.
Roivant Sciences Ltd.
Welcomes Patrick Machado to its Board of Directors, as its second independent director. Machado is Co-founder of Medivation where he served as CFO from 2004 to 2014. He also contributed on its Board of Directors from 2014 to 2016. He is currently an active member on the boards of Scynexis, Inc., Inotek Pharmaceuticals Corporation, Chimerix, Inc., and Armaron Bio Pty Ltd. where he serves as the Chairman of the board.